An evolving understanding of cancer biology has resulted in the rise of precision-informed treatment approaches. 

Recent years have seen a significant increase in the number of innovative oncology treatments entering clinical trials, with 4,000 emerging oncology therapy trials underway in 2023. In turn, the influx of emerging, innovative oncology therapies has shifted the clinical development landscape, introducing new hurdles and considerations for oncology developers, particularly biotechs developing oncology therapies with novel modalities.

To better understand the challenges and opportunities facing oncology developers, ICON surveyed over 100 oncology drug developers representing organisations ranging from small to large biotech and pharmaceutical companies from North America and Europe. Respondents provided their insights on the current and future landscape of oncology clinical research, and the limitations and challenges faced by therapeutic developers. 

This whitepaper reviews the most pressing challenges and opportunities facing the oncology therapeutic landscape in the emerging era of precision medicine, and reports on how those opportunities and challenges vary by organisational size and region. 

Explore the whitepaper to discover:

• How advancements in the molecular-genetic characterisation of cancer enabled a transition to precision-informed therapies in oncology
• Common challenges facing oncology therapeutic developers, and how they are adapting to an increasingly competitive and diverse market of high-risk, high-reward modalities
• Opportunities for de-risking and streamlining the clinical development of emerging oncology therapeutics – such as the employment of AI, facilitating collaboration between partners, vendors and trial sites, smarter dose-selection designs, and the integration of predictive biomarkers
• The role oncology drug developers can play to ensure that advances in precision medicine are successfully and equitably translated into the clinic